ClinicalTrials.gg

Program

trastuzumab brengitecan

Also written as “BL-M07D1”, “T-Bren, Dose level 1” and “T-bren, Dose level 2”.

In Sichuan Biokin Pharmaceutical's pipeline, HER2 ADC. Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Urinary Bladder Neoplasms · Endometrial Neoplasms · Colorectal Neoplasms, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 3, since Mar 12, 202421 company-led studies, 21 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical2121 open or runningphase 3since Mar 12, 2024Jul 14, 2022Dec 2026phase 2 · NCT06114511
  • Named in Sichuan Biokin Pharmaceutical’s own pipeline as T-Bren (BL-M07D1, HER2 ADC), phase 3, as of Nov 16, 2026 (source).

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jul 14, 2022.

  1. Feb 22, 2024Phase 1 study in Endometrial NeoplasmsNCT06293898 · 280 planned · United States
  2. Mar 12, 2024Phase 3 study in HER2-positive Breast CancerNCT06316531 · 274 enrolled · China
  3. May 16, 20242 phase 2 studiesNCT06423885, NCT06445400
  4. Feb 12, 2025Phase 3 study in HER2-positive Breast CancerNCT06830889 · 1,450 planned · China
  5. Mar 18, 2025Phase 3 study in HER2-positive Breast CancerNCT06891833 · 985 planned · China
  6. Apr 27, 2025Phase 3 study in HER2-low Breast CancerNCT06957886 · 566 planned · China
  7. Aug 26, 2025Phase 3 study in Gastric AdenocarcinomaNCT07152405 · 490 planned · China
  8. Sep 11, 2025Phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07178795 · 440 planned · China
  9. Nov 24, 2025Phase 2 study in Non-squamous Non-small Cell Lung CancerNCT07264816 · 80 planned · China
  10. Apr 2, 20262 phase 3 studiesNCT07518173, NCT07545460
  11. May 19, 2026Phase 3 study in Biliary Tract NeoplasmsNCT07606599 · 398 planned · China
  12. Jun 25, 2026Phase 2 study in Breast NeoplasmsNCT07678957 · 120 planned · China
  13. Jul 23, 2026Phase 3 study in Colorectal NeoplasmsNCT07730489 · 130 planned · China
  14. Oct 6, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07869836 · 520 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06114511
  2. Dec 2026Primary completion: phase 2 study in Her2-positive/Low-expression Urinary and Digestive Tract TumorsNCT06031584
  3. Dec 2026Primary completion: phase 1 study in Locally Advanced or Metastatic Digestive Tract TumorsNCT05631964
  4. Dec 2026Primary completion: phase 1 study in Breast NeoplasmsNCT05461768

TargetBeta

“HER2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07869836Urinary Bladder Neoplasms · United States3RecruitingDec 2028520
NCT07730489Colorectal Neoplasms · China3Not yet recruitingDec 2027130
NCT07678957Breast Neoplasms · China2RecruitingDec 2028120
NCT07606599Biliary Tract Neoplasms · China3RecruitingDec 2028398
NCT07545460Carcinoma, Ovarian Epithelial · China3Not yet recruitingDec 2028404
NCT07518173HER2-positive Breast Cancer · China3RecruitingDec 2029596
NCT07264816Non-squamous Non-small Cell Lung Cancer · China2RecruitingDec 202780
NCT07178795Non-squamous Non-small Cell Lung Cancer · China3RecruitingDec 2027440
NCT07152405Gastric Adenocarcinoma · China3RecruitingJun 2027490
NCT06957886HER2-low Breast Cancer · China3RecruitingMay 2027566
NCT06891833HER2-positive Breast Cancer · China3RecruitingDec 2028985
NCT06830889HER2-positive Breast Cancer · China3RecruitingOct 20311,450
NCT06445400HER2-positive Breast Cancer · China2Active, not recruitingJul 21, 202583
NCT06423885HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma · China2Active, not recruitingOct 202664
NCT06316531HER2-positive Breast Cancer · China3Active, not recruitingOct 2026274
NCT06293898Endometrial Neoplasms · United States1RecruitingDec 15, 2028280
NCT06131450Gynecological Malignancies · China2RecruitingJan 2027158
NCT06114511Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingDec 202678
NCT06031584Her2-positive/Low-expression Urinary and Digestive Tract Tumors · China2RecruitingDec 202642
NCT05631964Locally Advanced or Metastatic Digestive Tract Tumors · China1RecruitingDec 202626
NCT05461768Breast Neoplasms · China1RecruitingDec 2026348

How it is read

Names in the registry

  • “BL-M07D1”, 20 entries
  • “T-Bren, Dose level 1”, 1 entry
  • “T-bren, Dose level 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.